摩通发表报告,指康方生物(09926.HK) 公布HARMONi-2总生存期(OS)数据更新,其整体OS数据相当强劲,风险比(HR)为0.73(置信区间0.57至0.95,p值0.009)。依沃西单抗(ivonescimab)组中位OS为30.8个月,较帕博利珠单抗(pembrolizumab)组的22.6个月长超过8个月。该行指出,HARMONi-2中帕博利珠单抗的中位OS较KEYNOTE-...
Source Link摩通发表报告,指康方生物(09926.HK) 公布HARMONi-2总生存期(OS)数据更新,其整体OS数据相当强劲,风险比(HR)为0.73(置信区间0.57至0.95,p值0.009)。依沃西单抗(ivonescimab)组中位OS为30.8个月,较帕博利珠单抗(pembrolizumab)组的22.6个月长超过8个月。该行指出,HARMONi-2中帕博利珠单抗的中位OS较KEYNOTE-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.